nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—Cytarabine—lymphatic system cancer	0.446	1	CrCtD
Lamivudine—Gemcitabine—Cytarabine—lymphatic system cancer	0.0989	0.373	CrCrCtD
Lamivudine—Zalcitabine—Cytarabine—lymphatic system cancer	0.0855	0.323	CrCrCtD
Lamivudine—DCK—Fludarabine—lymphatic system cancer	0.0715	0.289	CbGbCtD
Lamivudine—DCK—Cytarabine—lymphatic system cancer	0.0488	0.197	CbGbCtD
Lamivudine—Cytarabine—Fludarabine—lymphatic system cancer	0.0435	0.164	CrCrCtD
Lamivudine—Decitabine—Cytarabine—lymphatic system cancer	0.0372	0.14	CrCrCtD
Lamivudine—SLC22A2—Cytarabine—lymphatic system cancer	0.0141	0.057	CbGbCtD
Lamivudine—SLC22A1—Cytarabine—lymphatic system cancer	0.0122	0.0495	CbGbCtD
Lamivudine—ABCC3—Vincristine—lymphatic system cancer	0.012	0.0485	CbGbCtD
Lamivudine—SLC22A3—Vincristine—lymphatic system cancer	0.0113	0.0456	CbGbCtD
Lamivudine—ABCC1—Mitoxantrone—lymphatic system cancer	0.0107	0.0433	CbGbCtD
Lamivudine—ABCG2—Teniposide—lymphatic system cancer	0.0102	0.0414	CbGbCtD
Lamivudine—ABCC1—Vincristine—lymphatic system cancer	0.00736	0.0298	CbGbCtD
Lamivudine—ABCC3—Methotrexate—lymphatic system cancer	0.00726	0.0294	CbGbCtD
Lamivudine—ABCG2—Mitoxantrone—lymphatic system cancer	0.00716	0.029	CbGbCtD
Lamivudine—ABCC4—Methotrexate—lymphatic system cancer	0.00554	0.0224	CbGbCtD
Lamivudine—ABCC2—Vincristine—lymphatic system cancer	0.00545	0.0221	CbGbCtD
Lamivudine—ABCG2—Vincristine—lymphatic system cancer	0.00492	0.0199	CbGbCtD
Lamivudine—ABCC1—Methotrexate—lymphatic system cancer	0.00446	0.018	CbGbCtD
Lamivudine—ABCC2—Methotrexate—lymphatic system cancer	0.0033	0.0134	CbGbCtD
Lamivudine—ABCG2—Methotrexate—lymphatic system cancer	0.00298	0.0121	CbGbCtD
Lamivudine—ABCB1—Mitoxantrone—lymphatic system cancer	0.00258	0.0104	CbGbCtD
Lamivudine—SLC22A6—Methotrexate—lymphatic system cancer	0.00241	0.00977	CbGbCtD
Lamivudine—ABCB1—Vincristine—lymphatic system cancer	0.00178	0.00719	CbGbCtD
Lamivudine—ABCB1—Methotrexate—lymphatic system cancer	0.00108	0.00435	CbGbCtD
Lamivudine—Anaemia—Bleomycin—lymphatic system cancer	7.34e-05	0.00175	CcSEcCtD
Lamivudine—Feeling abnormal—Fludarabine—lymphatic system cancer	7.28e-05	0.00173	CcSEcCtD
Lamivudine—Asthenia—Teniposide—lymphatic system cancer	7.22e-05	0.00172	CcSEcCtD
Lamivudine—Malaise—Bleomycin—lymphatic system cancer	7.16e-05	0.0017	CcSEcCtD
Lamivudine—Pruritus—Teniposide—lymphatic system cancer	7.12e-05	0.00169	CcSEcCtD
Lamivudine—Leukopenia—Bleomycin—lymphatic system cancer	7.11e-05	0.00169	CcSEcCtD
Lamivudine—Alopecia—Carmustine—lymphatic system cancer	7.04e-05	0.00167	CcSEcCtD
Lamivudine—Body temperature increased—Fludarabine—lymphatic system cancer	6.99e-05	0.00166	CcSEcCtD
Lamivudine—Malnutrition—Carmustine—lymphatic system cancer	6.93e-05	0.00165	CcSEcCtD
Lamivudine—Erythema—Carmustine—lymphatic system cancer	6.93e-05	0.00165	CcSEcCtD
Lamivudine—Cough—Bleomycin—lymphatic system cancer	6.93e-05	0.00165	CcSEcCtD
Lamivudine—Aplastic anaemia—Methotrexate—lymphatic system cancer	6.9e-05	0.00164	CcSEcCtD
Lamivudine—Diarrhoea—Teniposide—lymphatic system cancer	6.88e-05	0.00164	CcSEcCtD
Lamivudine—Mediastinal disorder—Vincristine—lymphatic system cancer	6.85e-05	0.00163	CcSEcCtD
Lamivudine—Chest pain—Bleomycin—lymphatic system cancer	6.76e-05	0.00161	CcSEcCtD
Lamivudine—Myalgia—Bleomycin—lymphatic system cancer	6.76e-05	0.00161	CcSEcCtD
Lamivudine—Alopecia—Vincristine—lymphatic system cancer	6.72e-05	0.0016	CcSEcCtD
Lamivudine—Back pain—Carmustine—lymphatic system cancer	6.7e-05	0.00159	CcSEcCtD
Lamivudine—Discomfort—Bleomycin—lymphatic system cancer	6.68e-05	0.00159	CcSEcCtD
Lamivudine—Chills—Mitoxantrone—lymphatic system cancer	6.64e-05	0.00158	CcSEcCtD
Lamivudine—Mouth ulceration—Methotrexate—lymphatic system cancer	6.64e-05	0.00158	CcSEcCtD
Lamivudine—Urine output increased—Methotrexate—lymphatic system cancer	6.64e-05	0.00158	CcSEcCtD
Lamivudine—Gynaecomastia—Methotrexate—lymphatic system cancer	6.57e-05	0.00156	CcSEcCtD
Lamivudine—Alopecia—Mitoxantrone—lymphatic system cancer	6.54e-05	0.00156	CcSEcCtD
Lamivudine—Confusional state—Bleomycin—lymphatic system cancer	6.53e-05	0.00155	CcSEcCtD
Lamivudine—Hypersensitivity—Fludarabine—lymphatic system cancer	6.51e-05	0.00155	CcSEcCtD
Lamivudine—Tremor—Carmustine—lymphatic system cancer	6.49e-05	0.00154	CcSEcCtD
Lamivudine—Anaphylactic shock—Bleomycin—lymphatic system cancer	6.48e-05	0.00154	CcSEcCtD
Lamivudine—Oedema—Bleomycin—lymphatic system cancer	6.48e-05	0.00154	CcSEcCtD
Lamivudine—Erythema—Mitoxantrone—lymphatic system cancer	6.44e-05	0.00153	CcSEcCtD
Lamivudine—Infection—Bleomycin—lymphatic system cancer	6.44e-05	0.00153	CcSEcCtD
Lamivudine—Anaemia—Carmustine—lymphatic system cancer	6.41e-05	0.00152	CcSEcCtD
Lamivudine—Back pain—Vincristine—lymphatic system cancer	6.4e-05	0.00152	CcSEcCtD
Lamivudine—Vomiting—Teniposide—lymphatic system cancer	6.39e-05	0.00152	CcSEcCtD
Lamivudine—Sepsis—Methotrexate—lymphatic system cancer	6.37e-05	0.00152	CcSEcCtD
Lamivudine—Thrombocytopenia—Bleomycin—lymphatic system cancer	6.35e-05	0.00151	CcSEcCtD
Lamivudine—Asthenia—Fludarabine—lymphatic system cancer	6.34e-05	0.00151	CcSEcCtD
Lamivudine—Rash—Teniposide—lymphatic system cancer	6.34e-05	0.00151	CcSEcCtD
Lamivudine—Dermatitis—Teniposide—lymphatic system cancer	6.34e-05	0.00151	CcSEcCtD
Lamivudine—Dysgeusia—Mitoxantrone—lymphatic system cancer	6.31e-05	0.0015	CcSEcCtD
Lamivudine—Headache—Teniposide—lymphatic system cancer	6.3e-05	0.0015	CcSEcCtD
Lamivudine—Pruritus—Fludarabine—lymphatic system cancer	6.25e-05	0.00149	CcSEcCtD
Lamivudine—Lymphadenopathy—Methotrexate—lymphatic system cancer	6.25e-05	0.00149	CcSEcCtD
Lamivudine—Back pain—Mitoxantrone—lymphatic system cancer	6.23e-05	0.00148	CcSEcCtD
Lamivudine—Leukopenia—Carmustine—lymphatic system cancer	6.2e-05	0.00148	CcSEcCtD
Lamivudine—Anorexia—Bleomycin—lymphatic system cancer	6.18e-05	0.00147	CcSEcCtD
Lamivudine—Anaemia—Vincristine—lymphatic system cancer	6.12e-05	0.00145	CcSEcCtD
Lamivudine—Polyuria—Methotrexate—lymphatic system cancer	6.07e-05	0.00144	CcSEcCtD
Lamivudine—Hypotension—Bleomycin—lymphatic system cancer	6.06e-05	0.00144	CcSEcCtD
Lamivudine—Diarrhoea—Fludarabine—lymphatic system cancer	6.05e-05	0.00144	CcSEcCtD
Lamivudine—Convulsion—Carmustine—lymphatic system cancer	6.01e-05	0.00143	CcSEcCtD
Lamivudine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	5.98e-05	0.00142	CcSEcCtD
Lamivudine—Nausea—Teniposide—lymphatic system cancer	5.97e-05	0.00142	CcSEcCtD
Lamivudine—Anaemia—Mitoxantrone—lymphatic system cancer	5.96e-05	0.00142	CcSEcCtD
Lamivudine—Vertigo—Vincristine—lymphatic system cancer	5.94e-05	0.00141	CcSEcCtD
Lamivudine—Leukopenia—Vincristine—lymphatic system cancer	5.92e-05	0.00141	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	5.9e-05	0.0014	CcSEcCtD
Lamivudine—Myalgia—Carmustine—lymphatic system cancer	5.9e-05	0.0014	CcSEcCtD
Lamivudine—Chest pain—Carmustine—lymphatic system cancer	5.9e-05	0.0014	CcSEcCtD
Lamivudine—Anxiety—Carmustine—lymphatic system cancer	5.88e-05	0.0014	CcSEcCtD
Lamivudine—Paraesthesia—Bleomycin—lymphatic system cancer	5.82e-05	0.00138	CcSEcCtD
Lamivudine—Malaise—Mitoxantrone—lymphatic system cancer	5.81e-05	0.00138	CcSEcCtD
Lamivudine—Dyspnoea—Bleomycin—lymphatic system cancer	5.78e-05	0.00137	CcSEcCtD
Lamivudine—Leukopenia—Mitoxantrone—lymphatic system cancer	5.77e-05	0.00137	CcSEcCtD
Lamivudine—Convulsion—Vincristine—lymphatic system cancer	5.73e-05	0.00136	CcSEcCtD
Lamivudine—Confusional state—Carmustine—lymphatic system cancer	5.7e-05	0.00136	CcSEcCtD
Lamivudine—Oedema—Carmustine—lymphatic system cancer	5.66e-05	0.00135	CcSEcCtD
Lamivudine—Decreased appetite—Bleomycin—lymphatic system cancer	5.63e-05	0.00134	CcSEcCtD
Lamivudine—Myalgia—Vincristine—lymphatic system cancer	5.63e-05	0.00134	CcSEcCtD
Lamivudine—Cough—Mitoxantrone—lymphatic system cancer	5.62e-05	0.00134	CcSEcCtD
Lamivudine—Infection—Carmustine—lymphatic system cancer	5.62e-05	0.00134	CcSEcCtD
Lamivudine—Vomiting—Fludarabine—lymphatic system cancer	5.62e-05	0.00134	CcSEcCtD
Lamivudine—Convulsion—Mitoxantrone—lymphatic system cancer	5.58e-05	0.00133	CcSEcCtD
Lamivudine—Rash—Fludarabine—lymphatic system cancer	5.57e-05	0.00133	CcSEcCtD
Lamivudine—Dermatitis—Fludarabine—lymphatic system cancer	5.57e-05	0.00132	CcSEcCtD
Lamivudine—Pain—Bleomycin—lymphatic system cancer	5.54e-05	0.00132	CcSEcCtD
Lamivudine—Thrombocytopenia—Carmustine—lymphatic system cancer	5.54e-05	0.00132	CcSEcCtD
Lamivudine—Headache—Fludarabine—lymphatic system cancer	5.54e-05	0.00132	CcSEcCtD
Lamivudine—Arthralgia—Mitoxantrone—lymphatic system cancer	5.49e-05	0.0013	CcSEcCtD
Lamivudine—Chest pain—Mitoxantrone—lymphatic system cancer	5.49e-05	0.0013	CcSEcCtD
Lamivudine—Myalgia—Mitoxantrone—lymphatic system cancer	5.49e-05	0.0013	CcSEcCtD
Lamivudine—Anxiety—Mitoxantrone—lymphatic system cancer	5.47e-05	0.0013	CcSEcCtD
Lamivudine—Discomfort—Mitoxantrone—lymphatic system cancer	5.42e-05	0.00129	CcSEcCtD
Lamivudine—Anaphylactic shock—Vincristine—lymphatic system cancer	5.4e-05	0.00128	CcSEcCtD
Lamivudine—Oedema—Vincristine—lymphatic system cancer	5.4e-05	0.00128	CcSEcCtD
Lamivudine—Anorexia—Carmustine—lymphatic system cancer	5.39e-05	0.00128	CcSEcCtD
Lamivudine—Infection—Vincristine—lymphatic system cancer	5.36e-05	0.00128	CcSEcCtD
Lamivudine—Feeling abnormal—Bleomycin—lymphatic system cancer	5.34e-05	0.00127	CcSEcCtD
Lamivudine—Confusional state—Mitoxantrone—lymphatic system cancer	5.3e-05	0.00126	CcSEcCtD
Lamivudine—Nervous system disorder—Vincristine—lymphatic system cancer	5.3e-05	0.00126	CcSEcCtD
Lamivudine—Thrombocytopenia—Vincristine—lymphatic system cancer	5.29e-05	0.00126	CcSEcCtD
Lamivudine—Hypotension—Carmustine—lymphatic system cancer	5.29e-05	0.00126	CcSEcCtD
Lamivudine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	5.26e-05	0.00125	CcSEcCtD
Lamivudine—Oedema—Mitoxantrone—lymphatic system cancer	5.26e-05	0.00125	CcSEcCtD
Lamivudine—Nausea—Fludarabine—lymphatic system cancer	5.25e-05	0.00125	CcSEcCtD
Lamivudine—Infection—Mitoxantrone—lymphatic system cancer	5.22e-05	0.00124	CcSEcCtD
Lamivudine—Hyperhidrosis—Vincristine—lymphatic system cancer	5.22e-05	0.00124	CcSEcCtD
Lamivudine—Shock—Mitoxantrone—lymphatic system cancer	5.17e-05	0.00123	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	5.15e-05	0.00123	CcSEcCtD
Lamivudine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	5.15e-05	0.00122	CcSEcCtD
Lamivudine—Urticaria—Bleomycin—lymphatic system cancer	5.15e-05	0.00122	CcSEcCtD
Lamivudine—Anorexia—Vincristine—lymphatic system cancer	5.15e-05	0.00122	CcSEcCtD
Lamivudine—Body temperature increased—Bleomycin—lymphatic system cancer	5.12e-05	0.00122	CcSEcCtD
Lamivudine—Insomnia—Carmustine—lymphatic system cancer	5.12e-05	0.00122	CcSEcCtD
Lamivudine—Skin disorder—Mitoxantrone—lymphatic system cancer	5.11e-05	0.00121	CcSEcCtD
Lamivudine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	5.08e-05	0.00121	CcSEcCtD
Lamivudine—Paraesthesia—Carmustine—lymphatic system cancer	5.08e-05	0.00121	CcSEcCtD
Lamivudine—Mood swings—Methotrexate—lymphatic system cancer	5.05e-05	0.0012	CcSEcCtD
Lamivudine—Hypotension—Vincristine—lymphatic system cancer	5.05e-05	0.0012	CcSEcCtD
Lamivudine—Dyspnoea—Carmustine—lymphatic system cancer	5.04e-05	0.0012	CcSEcCtD
Lamivudine—Somnolence—Carmustine—lymphatic system cancer	5.03e-05	0.0012	CcSEcCtD
Lamivudine—Anorexia—Mitoxantrone—lymphatic system cancer	5.01e-05	0.00119	CcSEcCtD
Lamivudine—Liver function test abnormal—Methotrexate—lymphatic system cancer	4.92e-05	0.00117	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	4.92e-05	0.00117	CcSEcCtD
Lamivudine—Decreased appetite—Carmustine—lymphatic system cancer	4.92e-05	0.00117	CcSEcCtD
Lamivudine—Hypotension—Mitoxantrone—lymphatic system cancer	4.91e-05	0.00117	CcSEcCtD
Lamivudine—Insomnia—Vincristine—lymphatic system cancer	4.88e-05	0.00116	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	4.88e-05	0.00116	CcSEcCtD
Lamivudine—Paraesthesia—Vincristine—lymphatic system cancer	4.85e-05	0.00115	CcSEcCtD
Lamivudine—Pain—Carmustine—lymphatic system cancer	4.84e-05	0.00115	CcSEcCtD
Lamivudine—Constipation—Carmustine—lymphatic system cancer	4.84e-05	0.00115	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	4.79e-05	0.00114	CcSEcCtD
Lamivudine—Hypersensitivity—Bleomycin—lymphatic system cancer	4.77e-05	0.00114	CcSEcCtD
Lamivudine—Paraesthesia—Mitoxantrone—lymphatic system cancer	4.72e-05	0.00112	CcSEcCtD
Lamivudine—Decreased appetite—Vincristine—lymphatic system cancer	4.69e-05	0.00112	CcSEcCtD
Lamivudine—Dyspnoea—Mitoxantrone—lymphatic system cancer	4.69e-05	0.00111	CcSEcCtD
Lamivudine—Somnolence—Mitoxantrone—lymphatic system cancer	4.68e-05	0.00111	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	4.66e-05	0.00111	CcSEcCtD
Lamivudine—Feeling abnormal—Carmustine—lymphatic system cancer	4.66e-05	0.00111	CcSEcCtD
Lamivudine—Fatigue—Vincristine—lymphatic system cancer	4.66e-05	0.00111	CcSEcCtD
Lamivudine—Asthenia—Bleomycin—lymphatic system cancer	4.65e-05	0.00111	CcSEcCtD
Lamivudine—Dyspepsia—Mitoxantrone—lymphatic system cancer	4.63e-05	0.0011	CcSEcCtD
Lamivudine—Gastrointestinal pain—Carmustine—lymphatic system cancer	4.63e-05	0.0011	CcSEcCtD
Lamivudine—Pain—Vincristine—lymphatic system cancer	4.62e-05	0.0011	CcSEcCtD
Lamivudine—Constipation—Vincristine—lymphatic system cancer	4.62e-05	0.0011	CcSEcCtD
Lamivudine—Pruritus—Bleomycin—lymphatic system cancer	4.59e-05	0.00109	CcSEcCtD
Lamivudine—Decreased appetite—Mitoxantrone—lymphatic system cancer	4.57e-05	0.00109	CcSEcCtD
Lamivudine—Fatigue—Mitoxantrone—lymphatic system cancer	4.53e-05	0.00108	CcSEcCtD
Lamivudine—Pancreatitis—Methotrexate—lymphatic system cancer	4.52e-05	0.00107	CcSEcCtD
Lamivudine—Pain—Mitoxantrone—lymphatic system cancer	4.5e-05	0.00107	CcSEcCtD
Lamivudine—Constipation—Mitoxantrone—lymphatic system cancer	4.5e-05	0.00107	CcSEcCtD
Lamivudine—Abdominal pain—Carmustine—lymphatic system cancer	4.47e-05	0.00106	CcSEcCtD
Lamivudine—Body temperature increased—Carmustine—lymphatic system cancer	4.47e-05	0.00106	CcSEcCtD
Lamivudine—Abdominal discomfort—Methotrexate—lymphatic system cancer	4.42e-05	0.00105	CcSEcCtD
Lamivudine—Gastrointestinal pain—Vincristine—lymphatic system cancer	4.42e-05	0.00105	CcSEcCtD
Lamivudine—Pancytopenia—Methotrexate—lymphatic system cancer	4.38e-05	0.00104	CcSEcCtD
Lamivudine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	4.33e-05	0.00103	CcSEcCtD
Lamivudine—Neutropenia—Methotrexate—lymphatic system cancer	4.31e-05	0.00102	CcSEcCtD
Lamivudine—Dysuria—Methotrexate—lymphatic system cancer	4.31e-05	0.00102	CcSEcCtD
Lamivudine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	4.3e-05	0.00102	CcSEcCtD
Lamivudine—Abdominal pain—Vincristine—lymphatic system cancer	4.27e-05	0.00102	CcSEcCtD
Lamivudine—Body temperature increased—Vincristine—lymphatic system cancer	4.27e-05	0.00102	CcSEcCtD
Lamivudine—Urticaria—Mitoxantrone—lymphatic system cancer	4.18e-05	0.000994	CcSEcCtD
Lamivudine—Hypersensitivity—Carmustine—lymphatic system cancer	4.17e-05	0.000991	CcSEcCtD
Lamivudine—Abdominal pain—Mitoxantrone—lymphatic system cancer	4.16e-05	0.000989	CcSEcCtD
Lamivudine—Body temperature increased—Mitoxantrone—lymphatic system cancer	4.16e-05	0.000989	CcSEcCtD
Lamivudine—Vomiting—Bleomycin—lymphatic system cancer	4.12e-05	0.00098	CcSEcCtD
Lamivudine—Depression—Methotrexate—lymphatic system cancer	4.1e-05	0.000974	CcSEcCtD
Lamivudine—Rash—Bleomycin—lymphatic system cancer	4.09e-05	0.000972	CcSEcCtD
Lamivudine—Dermatitis—Bleomycin—lymphatic system cancer	4.08e-05	0.000971	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	4.07e-05	0.000969	CcSEcCtD
Lamivudine—Asthenia—Carmustine—lymphatic system cancer	4.06e-05	0.000965	CcSEcCtD
Lamivudine—Renal failure—Methotrexate—lymphatic system cancer	4.04e-05	0.00096	CcSEcCtD
Lamivudine—Stomatitis—Methotrexate—lymphatic system cancer	4e-05	0.000952	CcSEcCtD
Lamivudine—Hypersensitivity—Vincristine—lymphatic system cancer	3.98e-05	0.000946	CcSEcCtD
Lamivudine—Sweating—Methotrexate—lymphatic system cancer	3.94e-05	0.000937	CcSEcCtD
Lamivudine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	3.89e-05	0.000924	CcSEcCtD
Lamivudine—Epistaxis—Methotrexate—lymphatic system cancer	3.88e-05	0.000922	CcSEcCtD
Lamivudine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	3.87e-05	0.000921	CcSEcCtD
Lamivudine—Asthenia—Vincristine—lymphatic system cancer	3.87e-05	0.000921	CcSEcCtD
Lamivudine—Diarrhoea—Carmustine—lymphatic system cancer	3.87e-05	0.00092	CcSEcCtD
Lamivudine—Nausea—Bleomycin—lymphatic system cancer	3.85e-05	0.000915	CcSEcCtD
Lamivudine—Agranulocytosis—Methotrexate—lymphatic system cancer	3.83e-05	0.000912	CcSEcCtD
Lamivudine—Asthenia—Mitoxantrone—lymphatic system cancer	3.77e-05	0.000897	CcSEcCtD
Lamivudine—Dizziness—Carmustine—lymphatic system cancer	3.74e-05	0.00089	CcSEcCtD
Lamivudine—Diarrhoea—Vincristine—lymphatic system cancer	3.69e-05	0.000879	CcSEcCtD
Lamivudine—Hepatitis—Methotrexate—lymphatic system cancer	3.69e-05	0.000877	CcSEcCtD
Lamivudine—Pharyngitis—Methotrexate—lymphatic system cancer	3.66e-05	0.00087	CcSEcCtD
Lamivudine—Diarrhoea—Mitoxantrone—lymphatic system cancer	3.6e-05	0.000856	CcSEcCtD
Lamivudine—Vomiting—Carmustine—lymphatic system cancer	3.6e-05	0.000855	CcSEcCtD
Lamivudine—Dizziness—Vincristine—lymphatic system cancer	3.57e-05	0.000849	CcSEcCtD
Lamivudine—Rash—Carmustine—lymphatic system cancer	3.57e-05	0.000848	CcSEcCtD
Lamivudine—Dermatitis—Carmustine—lymphatic system cancer	3.56e-05	0.000847	CcSEcCtD
Lamivudine—Headache—Carmustine—lymphatic system cancer	3.54e-05	0.000843	CcSEcCtD
Lamivudine—Erythema multiforme—Methotrexate—lymphatic system cancer	3.49e-05	0.000829	CcSEcCtD
Lamivudine—Vomiting—Vincristine—lymphatic system cancer	3.43e-05	0.000817	CcSEcCtD
Lamivudine—Rash—Vincristine—lymphatic system cancer	3.4e-05	0.00081	CcSEcCtD
Lamivudine—Dermatitis—Vincristine—lymphatic system cancer	3.4e-05	0.000809	CcSEcCtD
Lamivudine—Headache—Vincristine—lymphatic system cancer	3.38e-05	0.000804	CcSEcCtD
Lamivudine—Nausea—Carmustine—lymphatic system cancer	3.36e-05	0.000799	CcSEcCtD
Lamivudine—Vomiting—Mitoxantrone—lymphatic system cancer	3.34e-05	0.000795	CcSEcCtD
Lamivudine—Immune system disorder—Methotrexate—lymphatic system cancer	3.33e-05	0.000792	CcSEcCtD
Lamivudine—Mediastinal disorder—Methotrexate—lymphatic system cancer	3.32e-05	0.00079	CcSEcCtD
Lamivudine—Rash—Mitoxantrone—lymphatic system cancer	3.32e-05	0.000789	CcSEcCtD
Lamivudine—Dermatitis—Mitoxantrone—lymphatic system cancer	3.31e-05	0.000788	CcSEcCtD
Lamivudine—Chills—Methotrexate—lymphatic system cancer	3.31e-05	0.000787	CcSEcCtD
Lamivudine—Headache—Mitoxantrone—lymphatic system cancer	3.29e-05	0.000783	CcSEcCtD
Lamivudine—Alopecia—Methotrexate—lymphatic system cancer	3.26e-05	0.000775	CcSEcCtD
Lamivudine—Erythema—Methotrexate—lymphatic system cancer	3.21e-05	0.000763	CcSEcCtD
Lamivudine—Malnutrition—Methotrexate—lymphatic system cancer	3.21e-05	0.000763	CcSEcCtD
Lamivudine—Nausea—Vincristine—lymphatic system cancer	3.21e-05	0.000763	CcSEcCtD
Lamivudine—Dysgeusia—Methotrexate—lymphatic system cancer	3.14e-05	0.000748	CcSEcCtD
Lamivudine—Nausea—Mitoxantrone—lymphatic system cancer	3.12e-05	0.000743	CcSEcCtD
Lamivudine—Back pain—Methotrexate—lymphatic system cancer	3.11e-05	0.000739	CcSEcCtD
Lamivudine—Ill-defined disorder—Methotrexate—lymphatic system cancer	2.98e-05	0.000708	CcSEcCtD
Lamivudine—Anaemia—Methotrexate—lymphatic system cancer	2.97e-05	0.000706	CcSEcCtD
Lamivudine—Malaise—Methotrexate—lymphatic system cancer	2.9e-05	0.000689	CcSEcCtD
Lamivudine—Vertigo—Methotrexate—lymphatic system cancer	2.88e-05	0.000686	CcSEcCtD
Lamivudine—Leukopenia—Methotrexate—lymphatic system cancer	2.87e-05	0.000683	CcSEcCtD
Lamivudine—Cough—Methotrexate—lymphatic system cancer	2.8e-05	0.000666	CcSEcCtD
Lamivudine—Convulsion—Methotrexate—lymphatic system cancer	2.78e-05	0.000662	CcSEcCtD
Lamivudine—Myalgia—Methotrexate—lymphatic system cancer	2.73e-05	0.00065	CcSEcCtD
Lamivudine—Chest pain—Methotrexate—lymphatic system cancer	2.73e-05	0.00065	CcSEcCtD
Lamivudine—Arthralgia—Methotrexate—lymphatic system cancer	2.73e-05	0.00065	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	2.71e-05	0.000646	CcSEcCtD
Lamivudine—Discomfort—Methotrexate—lymphatic system cancer	2.7e-05	0.000642	CcSEcCtD
Lamivudine—Confusional state—Methotrexate—lymphatic system cancer	2.64e-05	0.000628	CcSEcCtD
Lamivudine—Anaphylactic shock—Methotrexate—lymphatic system cancer	2.62e-05	0.000623	CcSEcCtD
Lamivudine—Infection—Methotrexate—lymphatic system cancer	2.6e-05	0.000619	CcSEcCtD
Lamivudine—Nervous system disorder—Methotrexate—lymphatic system cancer	2.57e-05	0.000611	CcSEcCtD
Lamivudine—Thrombocytopenia—Methotrexate—lymphatic system cancer	2.57e-05	0.00061	CcSEcCtD
Lamivudine—Skin disorder—Methotrexate—lymphatic system cancer	2.55e-05	0.000605	CcSEcCtD
Lamivudine—Hyperhidrosis—Methotrexate—lymphatic system cancer	2.53e-05	0.000602	CcSEcCtD
Lamivudine—Anorexia—Methotrexate—lymphatic system cancer	2.5e-05	0.000594	CcSEcCtD
Lamivudine—Hypotension—Methotrexate—lymphatic system cancer	2.45e-05	0.000582	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	2.39e-05	0.000568	CcSEcCtD
Lamivudine—Insomnia—Methotrexate—lymphatic system cancer	2.37e-05	0.000564	CcSEcCtD
Lamivudine—Paraesthesia—Methotrexate—lymphatic system cancer	2.35e-05	0.00056	CcSEcCtD
Lamivudine—Dyspnoea—Methotrexate—lymphatic system cancer	2.34e-05	0.000556	CcSEcCtD
Lamivudine—Somnolence—Methotrexate—lymphatic system cancer	2.33e-05	0.000554	CcSEcCtD
Lamivudine—Dyspepsia—Methotrexate—lymphatic system cancer	2.31e-05	0.000548	CcSEcCtD
Lamivudine—Decreased appetite—Methotrexate—lymphatic system cancer	2.28e-05	0.000542	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	2.26e-05	0.000538	CcSEcCtD
Lamivudine—Fatigue—Methotrexate—lymphatic system cancer	2.26e-05	0.000537	CcSEcCtD
Lamivudine—Pain—Methotrexate—lymphatic system cancer	2.24e-05	0.000533	CcSEcCtD
Lamivudine—Feeling abnormal—Methotrexate—lymphatic system cancer	2.16e-05	0.000513	CcSEcCtD
Lamivudine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	2.14e-05	0.00051	CcSEcCtD
Lamivudine—Urticaria—Methotrexate—lymphatic system cancer	2.08e-05	0.000495	CcSEcCtD
Lamivudine—Abdominal pain—Methotrexate—lymphatic system cancer	2.07e-05	0.000493	CcSEcCtD
Lamivudine—Body temperature increased—Methotrexate—lymphatic system cancer	2.07e-05	0.000493	CcSEcCtD
Lamivudine—Hypersensitivity—Methotrexate—lymphatic system cancer	1.93e-05	0.000459	CcSEcCtD
Lamivudine—Asthenia—Methotrexate—lymphatic system cancer	1.88e-05	0.000447	CcSEcCtD
Lamivudine—Pruritus—Methotrexate—lymphatic system cancer	1.85e-05	0.000441	CcSEcCtD
Lamivudine—Diarrhoea—Methotrexate—lymphatic system cancer	1.79e-05	0.000426	CcSEcCtD
Lamivudine—Dizziness—Methotrexate—lymphatic system cancer	1.73e-05	0.000412	CcSEcCtD
Lamivudine—Vomiting—Methotrexate—lymphatic system cancer	1.67e-05	0.000396	CcSEcCtD
Lamivudine—Rash—Methotrexate—lymphatic system cancer	1.65e-05	0.000393	CcSEcCtD
Lamivudine—Dermatitis—Methotrexate—lymphatic system cancer	1.65e-05	0.000393	CcSEcCtD
Lamivudine—Headache—Methotrexate—lymphatic system cancer	1.64e-05	0.00039	CcSEcCtD
Lamivudine—Nausea—Methotrexate—lymphatic system cancer	1.56e-05	0.00037	CcSEcCtD
